NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the benefits of NGS in oncology.
- Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and other specialists highlight the impact of NGS on personalized treatment approaches.
No specific quotes are provided in the given text.
Authors include Naval G. Daver, MD, Jessica Altman, MD, and Estelamari Rodriguez, MD, MPH, among others, contributing to the discussion on NGS and biomarker testing.
Author's summary: NGS improves biomarker testing in solid tumors.